DE
Ahzantive
Informationen über Ahzantive® für Patienten und Angehörige der Fachkreise
Ahzantive® (Aflibercept)
Leitfaden für die sichere Anwendung –
Patientinnen und Patienten
Ahzantive® (Aflibercept)
Leitfaden zur Verringerung von
Arzneimittel- und Anwendungsrisiken –
Angehörige der Heilberufe
Meldung von
Nebenwirkungen
Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker.
Dies gilt auch für Nebenwirkungen, die nicht in der Packungsbeilage angegeben sind. Sie können Nebenwirkungen auch direkt dem
Bundesinstitut für Arzneimittel und Medizinprodukte,
Abt. Pharmakovigilanz,
Kurt-Georg-Kiesinger-Allee 3,
53175 Bonn,
Website: http://www.bfarm.de/
anzeigen.
Indem Sie Nebenwirkungen melden, können Sie dazu beitragen, dass mehr Informationen über die Sicherheit dieses Arzneimittels zur Verfügung gestellt werden.
Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Sie können dabei helfen, indem Sie jede auftretende Nebenwirkung melden.
Das Bundesinstitut für Arzneimittel und Medizinprodukte stellt für die Meldung von Nebenwirkungen ein Online-Formular zur Verfügung:
Darüber hinaus können Sie Nebenwirkungen per E-Mail an die Formycon AG melden. Bitte geben Sie bei der Meldung unbedingt den Namen des Medikaments sowie die Chargennummer an. Die Chargennummer (CH.-B.) ist eine Buchstaben- und Zahlenkombination, die Sie auf der Medikamentenverpackung zusammen mit der Seriennummer und dem Haltbarkeitsdatum finden.
medinfo@formycon.com
Bitte beachten Sie die Hinweise zum
Datenschutz.
DE
Ahzanive
Informatie over Ahzantive® voor patiënten en professionals in de gezondheidszorg
Risico minimalisatie materiaal betreffende informatie over Ahzantive® voor patiënten
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
DME
(diabetisch
maculaoedeem)
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
LMD
(neovasculaire (natte) leeftijdsgebonden maculadegeneratie)
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
mCNV
(myope choroïdale neovascularisatie)
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
RVO
(retinale veneuze
occlusie)
Risicominimalisatie-materiaal over de risico’s van aflibercept voor voorschrijvers en video over de intravitreale injectieprocedure
Risicominimalisatie-
materiaal over de risico’s
van aflibercept voor
voorschrijvers
Ahzantive®
40 mg/ml oplossing voor injectie in een injectieflacon
Video over de intravitreale injectieprocedure voor beroepsbeoefenaren in de gezondheidszorg
Ahzantive®
40 mg/ml oplossing voor injectie in een injectieflacon
Bijwerkingen
Neem contact op met uw arts, apotheker of verpleegkundigen als u last krijgt van bijwerkingen. Dat geldt ook voor mogelijke bijwerkingen die niet in de bijsluiter staan.
Door deze bijwerkingen te melden kunt u helpen meer informatie te geven over de veiligheid van dit medicijn.
U kunt bijwerkingen melden via het Nederlands Bijwerkingencentrum Lareb.
U kunt bijwerkingen ook per e-mail melden via:
medinfo@formycon.com
Verwerking van de gegevens gebeurt altijd in overeenstemming met de wettelijke vereisten. Meer informatie vindt u hier.
wAMD
Ahzantive
wAMD
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
mCNV
Ahzantive
mCNV
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
CRVO
Ahzantive
CRVO
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
BRVO
Ahzantive
BRVO
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
DMO
Ahzantive
DMO
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
Audioguide
Ahzantive
Guia do Doente
Informação de segurança sobre o tratamento com:
Ahzantive▼ / Baiama▼
▼ Este medicamento está sujeito a monitorização adicional. Isto irá permitir a rápida identificação de nova informação de segurança. Poderá ajudar, comunicando quaisquer efeitos indesejáveis que tenha.
Versão 1, Novembro 2025
Este guia para o doente constitui uma obrigação para o uso seguro do medicamento, foi desenvolvido com o acordo do INFARMED, I.P. e fornece-lhe informação de segurança importante sobre este medicamento.
Para obter mais informações poderá consultar o folheto informativo, disponível no sítio do INFARMED, I.P., em Infomed – https://extranet.infarmed.pt/INFOMED-fo/
O folheto informativo, o guia do doente e esta versão áudio também podem ser encontrados digitalizando o código QR que consta no guia do doente.
Se, após a leitura deste guia e do folheto informativo, ainda tiver questões ou dúvidas sobre a utilização deste medicamento, fale com o seu médico oftalmologista.
Antes de iniciar o seu tratamento com Aflibercept, leia atentamente este material educacional.
O QUE É Ahzantive /Baiama?
Estes medicamentos consistem numa solução que é injetada no olho e a dose recomendada é de 2 mg de aflibercept, equivalente a 0,05 ml de solução. O tratamento inicia-se com uma injeção por mês, durante três doses consecutivas, seguida por uma injeção a cada dois meses. Com base na avaliação médica, o intervalo entre tratamentos pode ser mantido por dois meses ou ser prolongado.
Estão indicados para o tratamento das seguintes doenças oculares em adultos:
- degenerescência macular relacionada com a idade (DMI) neovascular (húmida),
- perda da visão devida a edema macular secundário a oclusão da veia retiniana (oclusão de ramo da veia retiniana [ORVR] ou oclusão da veia central da retina [OVCR]),
- perda da visão devida a edema macular diabético (EMD),
- perda da visão devida a neovascularização coroideia associada à miopia patológica (NVCm).
ANTES DA INJEÇÃO
Antes da sua injeção é importante informar o seu médico se:
- tem uma infeção no olho ou à sua volta;
- tem atualmente dor ou vermelhidão no seu olho;
- pensa que tem alergia (hipersensibilidade) ao aflibercept ou a qualquer outro componente de Aflibercept, ao iodo ou a anestésicos;
- teve anteriormente problemas com injeções nos olhos;
- tem glaucoma ou antecedentes de aumento da pressão no interior do olho;
- tem antecedentes de ver luzes intensas repentinas ou manchas;
- foi submetido a cirurgia ao olho nas últimas quatro semanas ou está planeada cirurgia nas próximas quatro semanas;
- tem uma doença do olho causada por diabetes (retinopatia diabética);
- estiver a tomar ou tiver tomado recentemente outros medicamentos,
- incluindo medicamentos obtidos sem receita médica;
- estiver grávida ou se existe a possibilidade de engravidar (ver abaixo).
Não use maquilhagem no dia marcado para o tratamento.
Deve assegurar-se de que é acompanhado por alguém que o possa levar a casa, uma vez que a sua visão ficará temporariamente afetada e não será capaz de conduzir imediatamente após a injeção.
A INJEÇÃO
Um médico ou enfermeiro irão prepará-lo para o tratamento:
- Será administrado um anestésico local diretamente no olho;
- Será utilizado um desinfetante para limpar cuidadosamente o seu olho e a pele à volta;
- A sua face será coberta com um campo cirúrgico especial;
- O seu olho será mantido aberto para que não possa pestanejar;
Um médico irá administrar-lhe a injeção na parte branca do seu olho:
- Pode sentir uma ligeira pressão à medida que lhe é administrada a injeção.
DEPOIS DA INJEÇÃO
- O seu médico pode efetuar alguns exames oftalmológicos, que podem incluir a medição da pressão no olho;
- Logo após o tratamento a sua visão estará turva. Se normalmente conduz, não deve conduzir até a sua visão voltar ao normal. Deixe alguém levá-lo a casa;
- Poderá ficar com o olho congestionado/ vermelho (hemorragia conjuntival). Se esta vermelhidão não desaparecer em alguns dias ou se se agravar, informe o seu médico;
- Poderá ver manchas móveis na sua visão (flocos vítreos). Se estes flocos vítreos não desaparecerem em poucos dias ou se agravarem, informe o seu médico;
- Poderá sentir dor no olho depois da injeção. Se a dor se agravar ou se não desaparecer completamente em poucos dias, informe o seu médico;
- As injeções podem causar outros efeitos indesejáveis (consulte o Folheto Informativo).
Após a injeção, se sentir uma diminuição súbita na visão ou um aumento da dor e vermelhidão no seu olho, contacte imediatamente o seu médico.
EFEITOS INDESEJÁVEIS POSSÍVEIS
Esteja atento a quaisquer alterações que ocorram no seu olho após a injeção, nomeadamente as seguintes, que podem ser graves:
- Inflamação no interior do olho (endoftalmite);
- Turvação do cristalino (catarata);
- Aumento da pressão no interior do olho;
- Diminuição da nitidez da visão (rasgadura do epitélio pigmentado da retina).
Em caso de ocorrência de alguma destas alterações, entre imediatamente em contacto com o seu médico.
GRAVIDEZ
As mulheres com potencial para engravidar têm de utilizar métodos contracetivos eficazes durante o tratamento com aflibercept e durante pelo menos 3 meses após a última injeção deste medicamento.
Existem dados limitados sobre a utilização deste medicamento em mulheres grávidas, pelo que não deve ser utilizado durante a gravidez, a menos que o potencial benefício justifique o potencial risco para a criança não nascida. Se está grávida ou planeia engravidar, discuta este assunto com o seu médico antes do tratamento com este medicamento.
NOTIFICAÇÃO DE EFEITOS INDESEJÁVEIS
Se tiver quaisquer efeitos indesejáveis, incluindo possíveis efeitos indesejáveis não indicados neste guia, fale com o seu médico. Também poderá comunicar efeitos indesejáveis diretamente ao INFARMED, I.P. ou ao representante do Titular de AIM através dos contactos que constam no guia do doente..
Ao comunicá-los, estará a ajudar a fornecer mais informações sobre a segurança deste medicamento.
Caso ainda tenha dúvidas sobre a utilização de aflibercept, fale com o seu médico.
EN
Ahzantive
Information about Ahzantive® for Patients and Healthcare Professionals
Ahzantive® (aflibercept)
Package leaflet: Information for the adult patient
Information for the adult patient
Ahzantive®
40 mg/ml
solution for
injection in
a vial
Information for the adult patient
Ahzantive®
40 mg/ml solution for injection in pre-filled syringe
Ahzantive® (aflibercept)
Summary of Product Characteristics
Summary of Product Characteristics –
Information for Health Care Professionals
Ahzantive®
40 mg/ml
solution for
injection in
a vial
Summary of Product Characteristics –
Information for Health Care Professionals
Ahzantive®
40 mg/ml solution for injection in pre-filled syringe
Patient booklet –
your guide to Ahzantive® (aflibercept)
Prescriber Guide to intravitreal injections with Ahzantive® (aflibercept)
Prescriber Guide
Ahzantive®
40 mg/ml solution for injection in a vial and
40 mg/ml solution for injection in pre-filled syringe
Reporting of side effects
If you notice any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.
You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk
Please ensure that you provide the brand name, and the specific batch-number.
By reporting side effects you can help provide more information on the safety of this medicine.
Alternatively you may report side effects by email to:
medinfo@formycon.com
The data processing is in accordance with the legal requirements. Further information can be found here.
UK
Ahzanive
Informatie over Ahzantive® voor patiënten en professionals in de gezondheidszorg
Risico minimalisatie materiaal betreffende informatie over Ahzantive® voor patiënten
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
DME
(diabetisch
maculaoedeem)
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
LMD
(neovasculaire (natte) leeftijdsgebonden maculadegeneratie)
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
mCNV
(myope choroïdale neovascularisatie)
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
RVO
(retinale veneuze
occlusie)
Risicominimalisatie-materiaal over de risico’s van aflibercept voor voorschrijvers en video over de intravitreale injectieprocedure
Risicominimalisatie-
materiaal over de risico’s
van aflibercept voor
voorschrijvers
Ahzantive®
40 mg/ml oplossing voor injectie in een injectieflacon
Video over de intravitreale injectieprocedure voor beroepsbeoefenaren in de gezondheidszorg
Ahzantive®
40 mg/ml oplossing voor injectie in een injectieflacon
Bijwerkingen
Neem contact op met uw arts, apotheker of verpleegkundigen als u last krijgt van bijwerkingen. Dat geldt ook voor mogelijke bijwerkingen die niet in de bijsluiter staan.
Door deze bijwerkingen te melden kunt u helpen meer informatie te geven over de veiligheid van dit medicijn.
U kunt bijwerkingen melden via het Nederlands Bijwerkingencentrum Lareb.
U kunt bijwerkingen ook per e-mail melden via:
medinfo@formycon.com
Verwerking van de gegevens gebeurt altijd in overeenstemming met de wettelijke vereisten. Meer informatie vindt u hier.
